Cargando…

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy

OBJECTIVE: To evaluate the radiological tumor response patterns and compare the response assessments based on immune-based therapeutics Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST 1.1 in metastatic clear-cell renal cell carcinoma (mccRCC) patients treated with programmed cell d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Bingjie, Shin, Ji Hoon, Li, Hailiang, Chen, Yanqiong, Guo, Yuan, Wang, Meiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909853/
https://www.ncbi.nlm.nih.gov/pubmed/33289356
http://dx.doi.org/10.3348/kjr.2020.0404
_version_ 1783656012009439232
author Zheng, Bingjie
Shin, Ji Hoon
Li, Hailiang
Chen, Yanqiong
Guo, Yuan
Wang, Meiyun
author_facet Zheng, Bingjie
Shin, Ji Hoon
Li, Hailiang
Chen, Yanqiong
Guo, Yuan
Wang, Meiyun
author_sort Zheng, Bingjie
collection PubMed
description OBJECTIVE: To evaluate the radiological tumor response patterns and compare the response assessments based on immune-based therapeutics Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST 1.1 in metastatic clear-cell renal cell carcinoma (mccRCC) patients treated with programmed cell death-1 (PD-1) inhibitors. MATERIALS AND METHODS: All mccRCC patients treated with PD-1 inhibitors at Henan Cancer Hospital, China, between January 2018 and April 2019, were retrospectively studied. A total of 30 mccRCC patients (20 males and 10 females; mean age, 55.6 years; age range, 37–79 years) were analyzed. The target lesions were quantified on consecutive CT scans during therapy using iRECIST and RECIST 1.1. The tumor growth rate was calculated before and after therapy initiation. The response patterns were analyzed, and the differences in tumor response assessments of the two criteria were compared. The intra- and inter-observer variabilities of iRECIST and RECIST 1.1 were also analyzed. RESULTS: The objective response rate throughout therapy was 50% (95% confidence interval [CI]: 32.1–67.9) based on iRECIST and 30% (95% CI: 13.6–46.4) based on RECIST 1.1. The time-to-progression (TTP) based on iRECIST was longer than that based on RECIST 1.1 (median TTP: not reached vs. 170 days, p = 0.04). iRECIST and RECIST 1.1 were discordant in 8 cases, which were evaluated as immune-unconfirmed PD based on iRECIST and PD based on RECIST 1.1. Six patients (20%, 6/30) had pseudoprogression based on iRECIST, of which four demonstrated early pseudoprogression and two had delayed pseudoprogression. Significant differences in the tumor response assessments based on the two criteria were observed (p < 0.001). No patients demonstrated hyperprogression during the study period. CONCLUSION: Our study confirmed that the iRECIST criteria are more capable of capturing immune-related atypical responses during immunotherapy, whereas conventional RECIST 1.1 may underestimate the benefit of PD-1 inhibitors. Pseudoprogression is not rare in mccRCC patients during PD-1 inhibitor therapy, and it may last for more than the recommended maximum of 8 weeks, indicating a limitation of the current strategy for immune response monitoring.
format Online
Article
Text
id pubmed-7909853
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Radiology
record_format MEDLINE/PubMed
spelling pubmed-79098532021-03-04 Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy Zheng, Bingjie Shin, Ji Hoon Li, Hailiang Chen, Yanqiong Guo, Yuan Wang, Meiyun Korean J Radiol Genitourinary Imaging OBJECTIVE: To evaluate the radiological tumor response patterns and compare the response assessments based on immune-based therapeutics Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST 1.1 in metastatic clear-cell renal cell carcinoma (mccRCC) patients treated with programmed cell death-1 (PD-1) inhibitors. MATERIALS AND METHODS: All mccRCC patients treated with PD-1 inhibitors at Henan Cancer Hospital, China, between January 2018 and April 2019, were retrospectively studied. A total of 30 mccRCC patients (20 males and 10 females; mean age, 55.6 years; age range, 37–79 years) were analyzed. The target lesions were quantified on consecutive CT scans during therapy using iRECIST and RECIST 1.1. The tumor growth rate was calculated before and after therapy initiation. The response patterns were analyzed, and the differences in tumor response assessments of the two criteria were compared. The intra- and inter-observer variabilities of iRECIST and RECIST 1.1 were also analyzed. RESULTS: The objective response rate throughout therapy was 50% (95% confidence interval [CI]: 32.1–67.9) based on iRECIST and 30% (95% CI: 13.6–46.4) based on RECIST 1.1. The time-to-progression (TTP) based on iRECIST was longer than that based on RECIST 1.1 (median TTP: not reached vs. 170 days, p = 0.04). iRECIST and RECIST 1.1 were discordant in 8 cases, which were evaluated as immune-unconfirmed PD based on iRECIST and PD based on RECIST 1.1. Six patients (20%, 6/30) had pseudoprogression based on iRECIST, of which four demonstrated early pseudoprogression and two had delayed pseudoprogression. Significant differences in the tumor response assessments based on the two criteria were observed (p < 0.001). No patients demonstrated hyperprogression during the study period. CONCLUSION: Our study confirmed that the iRECIST criteria are more capable of capturing immune-related atypical responses during immunotherapy, whereas conventional RECIST 1.1 may underestimate the benefit of PD-1 inhibitors. Pseudoprogression is not rare in mccRCC patients during PD-1 inhibitor therapy, and it may last for more than the recommended maximum of 8 weeks, indicating a limitation of the current strategy for immune response monitoring. The Korean Society of Radiology 2021-03 2020-11-26 /pmc/articles/PMC7909853/ /pubmed/33289356 http://dx.doi.org/10.3348/kjr.2020.0404 Text en Copyright © 2021 The Korean Society of Radiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Genitourinary Imaging
Zheng, Bingjie
Shin, Ji Hoon
Li, Hailiang
Chen, Yanqiong
Guo, Yuan
Wang, Meiyun
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title_full Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title_fullStr Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title_full_unstemmed Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title_short Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
title_sort comparison of radiological tumor response based on irecist and recist 1.1 in metastatic clear-cell renal cell carcinoma patients treated with programmed cell death-1 inhibitor therapy
topic Genitourinary Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909853/
https://www.ncbi.nlm.nih.gov/pubmed/33289356
http://dx.doi.org/10.3348/kjr.2020.0404
work_keys_str_mv AT zhengbingjie comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy
AT shinjihoon comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy
AT lihailiang comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy
AT chenyanqiong comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy
AT guoyuan comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy
AT wangmeiyun comparisonofradiologicaltumorresponsebasedonirecistandrecist11inmetastaticclearcellrenalcellcarcinomapatientstreatedwithprogrammedcelldeath1inhibitortherapy